使用乙肝核心抗体阳性供肝并单药抗病毒预防的肝移植
这项回顾性研究纳入香港玛丽医院2000至2015年964例成人肝移植,其中416例(43.2%)供肝抗-HBc阳性、548例(56.8%)阴性,抗-HBc阳性供肝受者接受抗病毒单药预防。中位随访7.8年,两组围手术期结局及1、5、10年移植物和患者生存率均相似;108例HBsAg阴性受者接受抗-HBc阳性供肝,新发HBV风险为3/108(2.8%)且均发生在拉米夫定时代。
要点
- 抗-HBc阳性与阴性供肝组的1、5、10年移植物生存率分别为93.3%、85.3%、76.8%与92.5%、82.9%、78.4%(p=0.944)。
- 抗-HBc阳性供肝组与阴性组1、5、10年患者生存率分别为94.2%、87%、79%与93.5%、84%、79.7%(p=0.712)。
- 108例HBsAg阴性受者接受抗-HBc阳性供肝,新发HBV风险3/108(2.8%),均发生在拉米夫定时代。
核心结论
- 新发HBV感染极罕见,尤其是使用恩替卡韦预防时;抗-HBc阳性供肝不影响移植后围手术期及长期结局。
- 作者认为这为有需要时临床使用乙肝核心抗体阳性供肝提供了支持。
研究设计与样本
- 回顾性研究,纳入2000至2015年在香港玛丽医院接受肝移植的所有成人,数据来自前瞻性收集的数据库。
- 共964例肝移植,供肝抗-HBc阳性416例(43.2%)、阴性548例(56.8%),中位随访7.8年。
- 接受抗-HBc阳性供肝的患者给予抗病毒单药预防。
主要发现
- 两组围手术期结局(住院死亡率、并发症、原发性无功能及移植物功能延迟)相似。
- 抗-HBc阳性组与阴性组1、5、10年移植物生存率分别为93.3%、85.3%、76.8%与92.5%、82.9%、78.4%(p=0.944)。
- 抗-HBc阳性组与阴性组1、5、10年患者生存率分别为94.2%、87%、79%与93.5%、84%、79.7%(p=0.712)。
- 108例HBsAg阴性受者接受抗-HBc阳性供肝,其中64例接受拉米夫定、44例接受恩替卡韦单药预防,新发HBV风险为3/108(2.8%)且均发生在拉米夫定时代。
- 659例HBsAg阳性患者中308例(46.7%)接受抗-HBc阳性供肝,两组HBV复发风险相似;供者抗-HBc状态不影响长期患者及移植物生存或肝细胞癌复发风险。
临床怎么用
- 作者认为这为有需要时临床使用乙肝核心抗体阳性供肝提供了支持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The impact of hepatitis B core antibody (anti-HBc) positive liver grafts on survival and the risk of de novo hepatitis B virus (HBV) infection after liver transplantation (LT) remain controversial. Therefore, we aimed to analyze this risk and the associated outcomes in a large cohort of patients. METHODS: This was a retrospective study that included all adults who underwent LT at Queen Mary Hospital, Hong Kong, between 2000 and 2015. Data were retrieved from a prospectively collected database. Antiviral monotherapy prophylaxis was given for patients receiving grafts from anti-HBc positive donors. RESULTS: A total of 964 LTs were performed during the study period, with 416 (43.2%) anti-HBc positive and 548 (56.8%) anti-HBc negative donors. The median follow-up time was 7.8 years. Perioperative outcomes (hospital mortality, complications, primary nonfunction and delayed graft function) were similar between the 2 groups. The 1-, 5- and 10-year graft survival rates were comparable in anti-HBc positive (93.3%, 85.3% and 76.8%) and anti-HBc negative groups (92.5%, 82.9% and 78.4%, p = 0.944). The 1-, 5- and 10-year patient survival rates in anti-HBc positive group were 94.2%, 87% and 79% and were similar to the anti-HBc negative group (93.5%, 84% and 79.7%, p = 0.712). One-hundred and eight HBsAg negative recipients received anti-HBc positive grafts, of whom 64 received lamivudine and 44 entecavir monotherapy prophylaxis. The risk of de novo HBV was 3/108 (2.8%) and all occurred in the lamivudine era. There were 659 HBsAg-positive patients and 308 (46.7%) received anti-HBc positive grafts. The risk of HBV recurrence was similar between the 2 groups. Donor anti-HBc status did not impact on long-term patient and graft survival, or the risk of hepatocellular carcinoma recurrence after LT. CONCLUSIONS: De novo HBV was exceedingly rare especially with entecavir prophylaxis. Anti-HBc positive grafts did not impact on perioperative and long-term outcomes after transplant. LAY SUMMARY: The risk of de novo hepatitis B infection after liver transplantation was rare when using hepatitis B core positive liver grafts with entecavir monotherapy prophylaxis. Hepatitis B core antibody status did not impact on perioperative and long-term outcomes after liver transplantation. This provides support for the clinical use of hepatitis B core positive liver grafts when required.
引用
- Wong TC, Fung JY, Cui TY, et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis. J Hepatol. 2019. PMID: 30871981. doi:10.1016/j.jhep.2019.03.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。